Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.76 |
| ▸ | ITGAV | P06756 | 20/20 | 0.76 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.76 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.76 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.76 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.56 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7507810 | 1.00 | ITGB3 (0.76) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL7507817 | 0.87 | ITGB3 (0.57) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL6178862 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL6178864 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL1824185 | 0.83 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL1824189 | 0.83 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL1825833 | 0.81 | ITGB3 (0.83) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL1825834 | 0.81 | ITGB3 (0.83) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL4786884 | 0.80 | ITGB3 (0.71) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL6178889 | 0.78 | ITGB3 (0.74) | ITGB3ITGAVITGB6ITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ITGB3 82/4885ITGAV 146/4885ITGB6 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.